3rd April 2023

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001 **BSE – AJANTPHARM 532331**	National Stock Exchange of India, Exchange Plaza, 5th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 **NSE AJANTPHARM EQ**	Audit Committee Ajanta Pharma Limited

Re: Disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir/ Madam,

Pursuant to provisions of Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, I hereby declare on behalf of promoters & promoter group of Ajanta Pharma Ltd. that we have not made any encumbrance, directly or indirectly, other than those already disclosed during the financial year ended 31st March 2023.

Thanking you,
Yours faithfully,

YOGESH MANNALAL AGRAWAL
Digitally signed by YOGESH MANNALAL AGRAWAL
Date: 2023.04.03 11:08:31 +05'30'

_____
YOGESH M. AGRAWAL

C.C. : The Company Secretary
Ajanta Pharma Limited
"Ajanta House",
Charkop, Kandivli (West)
Mumbai – 400 067